AU2013348112A1 - Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use - Google Patents

Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use Download PDF

Info

Publication number
AU2013348112A1
AU2013348112A1 AU2013348112A AU2013348112A AU2013348112A1 AU 2013348112 A1 AU2013348112 A1 AU 2013348112A1 AU 2013348112 A AU2013348112 A AU 2013348112A AU 2013348112 A AU2013348112 A AU 2013348112A AU 2013348112 A1 AU2013348112 A1 AU 2013348112A1
Authority
AU
Australia
Prior art keywords
cells
polypeptide
fusion protein
tumor
gadd45x
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013348112A
Other languages
English (en)
Inventor
Muhammad S. Alam
Jonathan D. Ashwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2013348112A1 publication Critical patent/AU2013348112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
AU2013348112A 2012-11-20 2013-11-19 Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use Abandoned AU2013348112A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261728368P 2012-11-20 2012-11-20
US61/728,368 2012-11-20
US201361774066P 2013-03-07 2013-03-07
US61/774,066 2013-03-07
PCT/US2013/070813 WO2014081728A1 (en) 2012-11-20 2013-11-19 Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use

Publications (1)

Publication Number Publication Date
AU2013348112A1 true AU2013348112A1 (en) 2015-05-28

Family

ID=50776497

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013348112A Abandoned AU2013348112A1 (en) 2012-11-20 2013-11-19 Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use

Country Status (6)

Country Link
US (1) US9359418B2 (https=)
EP (1) EP2922865A4 (https=)
JP (1) JP2016503425A (https=)
AU (1) AU2013348112A1 (https=)
CA (1) CA2891425A1 (https=)
WO (1) WO2014081728A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111206098B (zh) * 2020-02-10 2023-02-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） p38γ在制备胰腺癌预后诊断试剂中的应用
CN119236082A (zh) * 2024-10-16 2025-01-03 遵义医科大学附属医院 Mapk4激动剂在制备类风湿性关节炎药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613318B1 (en) * 1999-03-25 2003-09-02 The United States Of America As Represented By The Department Of Health And Human Services Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity
US7354898B2 (en) * 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
AU2004203373A1 (en) 2003-07-25 2005-02-10 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
WO2005077983A2 (en) * 2004-02-05 2005-08-25 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Modulating p38 kinase activity
US20100104536A1 (en) * 2007-03-20 2010-04-29 Indravadan Ambalal Modi P38 inhibitors

Also Published As

Publication number Publication date
JP2016503425A (ja) 2016-02-04
EP2922865A4 (en) 2016-06-29
US9359418B2 (en) 2016-06-07
US20160083442A1 (en) 2016-03-24
EP2922865A1 (en) 2015-09-30
WO2014081728A1 (en) 2014-05-30
WO2014081728A8 (en) 2015-06-18
CA2891425A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
Gorman et al. Regulation of T cell responses by the receptor molecule Tim-3
US20220315641A9 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP1931375B1 (en) Chemo-immunotherapy method
CA2807036C (en) Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
DK2627346T3 (en) Cell permeable peptide inhibitors of the JNK signal transduction pathway for use in the treatment of uveitis
US20190309046A1 (en) Signal transduction modifying protein
CN118165120A (zh) 一种嵌合抗原受体及其应用
EP3185885B1 (en) Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
KR102033215B1 (ko) 건선 유발 동물 모델 및 이의 용도
US9359418B2 (en) Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use
Li et al. The role of T cells in the development of Henoch-Schonlein purpura
JP2014505655A (ja) Ｎｄ２ペプチドおよび神経疾患の治療方法
US20110311558A1 (en) Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
KR101868620B1 (ko) Fgf12를 이용한 혈관 평활근세포 증식성 질환의 진단, 예방 또는 치료용 조성물
US9395368B2 (en) Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors
JP2017521408A (ja) 無毒性破傷風毒素ｃフラグメント（ｔｔｃ）を使用して筋量を増加させる方法
WO2020146639A2 (en) Compositions and methods for the diagnosis and treatment of diseases of the liver
JP2021523892A (ja) Ｏｃａ−ｂペプチドコンジュゲート及び処置方法
KR20230152070A (ko) 망막 신경절 세포의 변성을 감소시키는 방법
CN117062629A (zh) 用于减少视网膜神经节细胞的变性的方法
US9539315B2 (en) Methods, agents and peptides for inhibiting matrix metalloproteinase-2 signaling
Van Role of PACAP/PAC1 Signaling in Neuromodulation of the Immune System and Neuroprotection
Tam et al. Islet Tconv
Zohar et al. Targeted Overexpression of IL-18 Binding
De Franceschi CDKL5 Disorder: a Novel Therapeutic Strategy to Improve Brain Development in a Newly Generated CDKL5 ko Mouse Model

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period